Oxidative stress pathways in noncancerous human liver tissue to predict hepatocellular carcinoma recurrence: A prospective, multicenter study

The prediction of cancer recurrence holds the key to improvement of the postoperative prognosis of patients. In this study, the recurrence of early‐stage hepatocellular carcinoma (HCC) after curative hepatectomy was analyzed by the genome‐wide gene‐expression profiling on cancer tissue and the noncancerous liver tissue. Using the training set of 78 cases, the cytochrome P450 1A2 (CYP1A2) gene in noncancerous liver tissue was identified as the predictive candidate for postoperative recurrence (hazard ratio [HR], 0.447; 95% confidence interval [CI], 0.249‐0.808; P = 0.010). Multivariate analysis revealed the statistically significant advantage of CYP1A2 down‐regulation to predict recurrence (odds ratio, 0.534; 95% CI, 0.276‐0.916; P = 0.036), and the expression of CYP1A2 protein was confirmed immunohistochemically. An independently multi‐institutional cohort of 211 patients, using tissue microarrays, validated that loss of expression of CYP1A2 in noncancerous liver tissue as the only predictive factor of recurrence after curative hepatectomy for early‐stage HCC (HR, 0.480; 95% CI, 0.256‐0.902; P = 0.038). Gene set‐enrichment analysis revealed close association of CYP1A2 down‐regulation with oxidative stress pathways in liver tissue (P < 0.001, false discovery rate [FDR] = 0.042; P = 0.006, FDR = 0.035). Our results indicate these pathways as the molecular targets to prevent recurrence, as well as the potential prediction of the super high‐risk population of HCC using liver tissue. (HEPATOLOGY 2011;54:1273–1281)

[1]  Arthur Liberzon,et al.  Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. , 2011, Gastroenterology.

[2]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[3]  Y. Shukla,et al.  Resveratrol and cellular mechanisms of cancer prevention , 2011, Annals of the New York Academy of Sciences.

[4]  Bo Wang,et al.  Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2 , 2010, Drug metabolism reviews.

[5]  M. Uysal,et al.  The effect of carnosine treatment on prooxidant–antioxidant balance in liver, heart and brain tissues of male aged rats , 2010, Biogerontology.

[6]  J. Ranger-Moore,et al.  Hepatic Cytochrome P450 Enzyme Alterations in Humans with Progressive Stages of Nonalcoholic Fatty Liver Disease The online version of this article (available at http://dmd.aspetjournals.org) contains supplemental material. , 2009, Drug Metabolism and Disposition.

[7]  S. Arii,et al.  Molecularly targeted therapy for hepatocellular carcinoma , 2009, Cancer science.

[8]  D. Rimm,et al.  A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Kenji Ikeda,et al.  Gene expression in fixed tissues and outcome in hepatocellular carcinoma. , 2008, The New England journal of medicine.

[10]  S. Ishida,et al.  Decreased Expression of Cytochromes P450 1A2, 2E1, and 3A4 and Drug Transporters Na+-Taurocholate-Cotransporting Polypeptide, Organic Cation Transporter 1, and Organic Anion-Transporting Peptide-C Correlates with the Progression of Liver Fibrosis in Chronic Hepatitis C Patients , 2008, Drug Metabolism and Disposition.

[11]  Gary Hardiman,et al.  Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. , 2008, Cancer cell.

[12]  Y. Miki,et al.  Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy , 2008, The British journal of surgery.

[13]  F. Pépin,et al.  Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.

[14]  E. Domany,et al.  Molecular mechanisms of the chemopreventive effect on hepatocellular carcinoma development in Mdr2 knockout mice , 2007, Molecular Cancer Therapeutics.

[15]  Michael Schrader,et al.  Peroxisomes and oxidative stress. , 2006, Biochimica et biophysica acta.

[16]  T. Hanai,et al.  Specific Gene-Expression Profiles of Noncancerous Liver Tissue Predict the Risk for Multicentric Occurrence of Hepatocellular Carcinoma in Hepatitis C Virus–Positive Patients , 2006, Annals of Surgical Oncology.

[17]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  G. Glinsky,et al.  Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. , 2005, The Journal of clinical investigation.

[19]  J. Llovet,et al.  Updated treatment approach to hepatocellular carcinoma , 2005, Journal of Gastroenterology.

[20]  Li Mao,et al.  Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Nebert,et al.  Cyp1a2 protects against reactive oxygen production in mouse liver microsomes. , 2004, Free radical biology & medicine.

[22]  K. Wakame,et al.  Suppressive effects of Active Hexose Correlated Compound on the increased activity of hepatic and renal ornithine decarboxylase induced by oxidative stress. , 2003, Life sciences.

[23]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[24]  M. Makuuchi,et al.  Results of surgical and nonsurgical treatment for small‐sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan , 2000, Hepatology.

[25]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[26]  V. Mazzaferro,et al.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.

[27]  J. Fagan,et al.  Down-regulation of P4501A1 and P4501A2 mRNA expression in isolated hepatocytes by oxidative stress. , 1994, The Journal of biological chemistry.

[28]  R. Groszmann,et al.  American association for the study of liver diseases , 1992 .

[29]  S. Arii,et al.  The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. , 2010, Journal of hepatology.

[30]  S. Arii,et al.  Outcomes and recurrence of initially resectable hepatocellular carcinoma meeting milan criteria: Rationale for partial hepatectomy as first strategy. , 2007, Journal of the American College of Surgeons.

[31]  ndrea,et al.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.